New drug ABBV-722 put through interaction tests in healthy volunteers

NCT ID NCT07567781

Ongoing Knowledge-focused Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This early-stage study is testing whether a new drug called ABBV-722 changes how the body processes several common medications. Twelve healthy adults will take ABBV-722 along with a 'cocktail' of other drugs (midazolam, digoxin, pitavastatin, metformin, and sitagliptin) to see if their levels in the blood are affected. The main goal is to check for side effects and measure drug concentrations, helping to guide future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABBV-722
What this could lead to: If successful, this study will help doctors understand how ABBV-722 interacts with other medications, guiding safe dosing in future trials.
What could go wrong: This is a very early, small study in healthy volunteers, not patients. It only measures drug levels and safety, not whether ABBV-722 works for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Locations

Acpru /Id# 282184

Grayslake, Illinois, 60030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.